Key Highlights
•
A new study of 162 patients with lung disease linked to certain antibodies found that the drug rituximab was associated with an improvement in lung function after 12 months. This suggests that targeted immunosuppressive therapy could help preserve lung health in patients with this complex condition, which often involves scarring of the lungs.
Source →
•
A large study of over 2,200 patients with cardiac amyloidosis, a condition where protein builds up in the heart, found that nearly 40% of patients had reduced heart pumping function, not just the preserved function it’s typically known for. Integrating multiple heart measurements, not just the standard pump strength, created a better model to predict a patient’s risk, arguing for a more comprehensive diagnostic approach.
Source →
•
A clinical trial found that adding a structured anxiety therapy (exposure-based CBT) to intensive community mental health teams significantly reduced patients’ trait anxiety scores over 18 months. This shows that integrating specific psychological interventions into existing outreach services is feasible and can improve recovery-related outcomes for people with severe mental illness.
Source →
•
A phase 1 trial showed that a modified dosing regimen of the COVID-19 antiviral nirmatrelvir/ritonavir (150/100 mg daily) was safe and achieved adequate drug levels in patients with severe kidney impairment, including those on dialysis. This provides crucial evidence for how to safely treat a high-risk population that was previously excluded from standard dosing due to concerns about drug buildup.
Source →
•
A phase 3 trial for advanced lung cancer with specific genetic mutations found that adding chemotherapy (carboplatin-pemetrexed) to the targeted drug aumolertinib nearly doubled the median time before the cancer worsened compared to the targeted drug alone (19.8 vs. 16.5 months). This offers the first prospective evidence that intensifying treatment can benefit patients whose cancers have these co-occurring genetic alterations.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
